Hotel Novotel Barcelona City
Avenida Diagonal 201, 08018
This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development.
The summit will shed light on current challenges, best practices and the inside view of the future of ADCs.
We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in the ADCs landscape.
Key Practical Learning Points of the Summit:
Who Should Attend:
Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Managers, Clinical Development Experts and Scientists specialising in:
Dr. Eric Valeur Associate Director New Modalities & Lead Generation AstraZeneca, Sweden
Dr. Björn Hock Senior Director, Global Head ADCs & Targeted NBE Therapeutics Merck KGaA, Germany
Dr. Pernille Hemmingsen Associate Director CMC Project Manager Genmab, Denmark
Dr. Ling Xu Bioanalysis of Small Molecules & Antibody Drug Conjugates Mersana Therapeutics, Inc. (represented Millennium Pharmaceuticals, Inc., subsidiary of Takeda), US
Dr. Charlotte Hagman Chemical Biology / Biochemistry / Analytical Chemistry Novartis AG, Switzerland
Dr. Berthold Boedeker Global Biological Development WUP Bayer AG, Germany
Dr. Alex Lazar Director Analytical & Pharmaceutical Sciences ImmunoGen, Inc., US
Dr. Markus Walles Team Lead Metabolism DMPK/IDD Novartis AG, Switzerland
Dr. Cecilia Simonelli Head of Corporate Therapeutic Area: Oncology, Immunology & Anti-Infective Menarini-Ricerch Menarini Group, Italy
Ulrich Rümenapp Head of Launch Preparation and Coordination Bayer AG
Stephan Schmidt Sr. Vice President Process Science and Production Rentschler Biotechnologie GmbH
Lucia D'Amico Department of Biomedicine University Hospital Basel
Floris van Delft Founder and CSO & Prof. of Bioconjugate Chemistry SynAffix & Wageningen University
Christian Rohlff CEO Oxford BioTherapeutics
Ulf Grawunder CEO NBE-Therapeutics Ltd.
Laurent Ducry Head of Commercial Development for Bioconjugates Lonza
Andrew Kyle Team Leader Abzena
Jens Lohrmann Translational Clinical Oncology Novartis AG
Chrisof Seidl Department of Nuclear Medicine Department of Obstetrics and Gynecology Technische Universität München
Please, complete details below:
Please, complete details below and you will get Agenda via E-mail:
Please, complete details below and you will get 500 € Document Package: